Immunosuppressive Therapy and Hepatitis B Virus Reactivation

Koksal I.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.22, sa.3, ss.69-73, 2016 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 22 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.4274/vhd.48615
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.69-73
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Reactivation of hepatitis B virus (HBV) refers to reappearance of active necroinflammatory disease of the liver in an individual at an inactive hepatitis B surface antigen carrier state or who is known to have resolved HBV infection. Patients receiving immunosuppressive therapy for malignant, autoimmune or chronic rheumatic diseases are at risk for HBV reactivation and a flare of their HBV infection due to loss of HBV immune control. HBV reactivation can be prevented by antiviral prophylaxis. Antiviral drugs given after the initiation of immunosuppressive therapy are less effective for liver injury and should not be preferred.